How Is Prostate Cancer Diagnosed?

This content has been reviewed and approved by

Daniel P. Petrylak, MD
Associate Professor of Medicine
Director, Genitourinary Oncology Program
Columbia University Medical Center
 

To detect cancer in your prostate gland, it is key to get a screening that commonly involves giving a blood sample to measure your PSA (prostate-specific antigen) level and/or getting a digital rectal examination (DRE) of the prostate area from your doctor or health care provider. 

  • PSA is a substance produced by the prostate to make semen a liquid. A PSA blood test measures the level of prostate-specific antigen in your body. Higher amounts of PSA may be found in men who have prostate cancer. 
  • DRE is when a physician or nurse places a gloved lubricated finger into the rectum, examines the area, and feels the prostate gland. During the exam, the physician feels for abnormal shape, size, and texture of the prostate. Although this procedure may make you uneasy, discomfort is generally mild.

As recommended by your physician, PSA tests as well as DREs are usually conducted annually for men over the age of 50. Early detection is important. It can limit the disease or set you on the road to a cure.  If you are over 50, you should have an annual physical examination that includes these tests as well as urine tests and possibly other laboratory tests. 

  • Men in high-risk groups, such as African-Americans or those with a strong family history of prostate cancer, should consult their physicians about having these two tests at a younger age or more often.

If the results of the DRE or PSA are unusual, your physician may repeat the tests or request other procedures. To learn more about these other procedures click on the following link.

Additional Procedures to Identify Prostate Cancer

This content was last modified on August 07, 2007 .
Latest Cancer News
Zevalin® Confirmed Effective for Patients with Follicular Lymphoma Who Have Failed an Autologous Transplant

September 5, 2008 — Researchers from France have reported that five of eight patients with follicular lymphoma who had failed an autologous stem cell transplant achieved a complete remission with standard doses of Zevalin® (Yttrium-90 ((90)Y) ibritumomab tiuxetan). The details of this study appeared in an early online publication in Leukemia-Lymphoma of July 15, 2008.

Forty Percent of Postmenopausal Breast Cancers Preventable by Lifestyle Changes

September 5, 2008 — Researchers from the University of Wisconsin-Madison, the H. Lee Moffitt Cancer Center, Dartmouth Medical School, and the Fred Hutchinson Cancer Center have reported that 40.7% of postmenopausal breast cancer can be prevented by changes in lifestyle. The details of this study appeared in the August 15, 2008 issue of the American Journal of Epidemiology.

US FDA lists drugs under safety probes

September 5, 2008 — WASHINGTON (Reuters) - U.S. health officials said on Friday they are probing safety concerns with Eli Lilly and Co's antidepressant Cymbalta, Biogen Idec and Elan Corp's multiple sclerosis drug Tysabri and more than a dozen other medicines.

Select news items provided by Reuters Health